gsk2879552 has been researched along with Myelodysplastic-Syndromes* in 1 studies
1 trial(s) available for gsk2879552 and Myelodysplastic-Syndromes
| Article | Year |
|---|---|
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Topics: Benzoates; Cyclopropanes; Humans; Leukemia, Myeloid, Acute; Lysine; Myelodysplastic Syndromes | 2022 |